Exelixis 2016 Q4 Financial Results and Full Year Earnings

Exelixis presented its fourth quarter and full year 2016 financial results on February 27, 2017, providing updates on CABOMETYX commercialization and cabozantinib development pipeline. The company outlined 2017 guidance including anticipated clinical trial data from the CELESTIAL study and plans for debt repayment to de-leverage its balance sheet.